HALOZYME THERAPEUTICS, INC. — Net Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/88df3f59-754d-4849-bcf7-51344fc8de7a/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $316.9M | 2025-01-01 – 2025-12-31 | evidence 0001159036-26-000024 |
| FY 2024 | $444.1M | 2024-01-01 – 2024-12-31 | evidence 0001159036-25-000010 |
| FY 2023 | $281.6M | 2023-01-01 – 2023-12-31 | evidence 0001159036-24-000008 |
| FY 2022 | $202.1M | 2022-01-01 – 2022-12-31 | evidence 0001159036-23-000012 |
| FY 2021 | $402.7M | 2021-01-01 – 2021-12-31 | evidence 0001159036-22-000014 |
| FY 2020 | $129.1M | 2020-01-01 – 2020-12-31 | evidence 0001159036-21-000014 |
| FY 2019 | $-72.2M | 2019-01-01 – 2019-12-31 | evidence 0001159036-20-000013 |
| FY 2018 | $-80.3M | 2018-01-01 – 2018-12-31 | evidence 0001159036-19-000006 |
| FY 2017 | $63.0M | 2017-01-01 – 2017-12-31 | evidence 0001159036-18-000011 |
| FY 2016 | $-103.0M | 2016-01-01 – 2016-12-31 | evidence 0001159036-17-000014 |
| FY 2015 | $-32.2M | 2015-01-01 – 2015-12-31 | evidence 0001159036-16-000100 |
| FY 2014 | $-68.4M | 2014-01-01 – 2014-12-31 | evidence 0001159036-15-000041 |
| FY 2013 | $-83.5M | 2013-01-01 – 2013-12-31 | evidence 0001159036-15-000041 |
| FY 2012 | $-53.6M | 2012-01-01 – 2012-12-31 | evidence 0001159036-15-000041 |
| FY 2011 | $-19.8M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-107555 |
| FY 2010 | $-53.2M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-107555 |
| FY 2009 | $-58.4M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-107555 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
HALOZYME THERAPEUTICS, INC. — all facts · Revenue · Operating Income